中国中医药信息杂志
中國中醫藥信息雜誌
중국중의약신식잡지
CHINESE JOURNAL OF INFORMATION ON TRADITIONAL CHINESE MEDICINE
2014年
7期
22-24
,共3页
孙杰%韩敏娟%张旭辉%曹鹏鹏
孫傑%韓敏娟%張旭輝%曹鵬鵬
손걸%한민연%장욱휘%조붕붕
咳喘宁胶囊%慢性阻塞性肺疾病%随机对照试验
咳喘寧膠囊%慢性阻塞性肺疾病%隨機對照試驗
해천저효낭%만성조새성폐질병%수궤대조시험
Kechuanning capsules%COPD%random-controlled trial
目的:观察咳喘宁胶囊治疗稳定期慢性阻塞性肺疾病(COPD)的临床疗效。方法将110例稳定期COPD患者随机分为治疗组和对照组各55例。2组均予复方异丙托溴铵溶液气雾吸入,在此基础上,治疗组口服咳喘宁胶囊,每次4粒,每日3次;对照组口服等剂量安慰剂胶囊。疗程均为3个月。观察2组患者临床疗效、BODE 指数、COPD 评估测试(CAT)评分及不良反应。结果治疗组与对照组分别脱落5、4例。治疗组临床总有效率为96.00%(48/50),对照组为88.24%(45/51),2组比较差异有统计学意义(P<0.05)。2组治疗后BODE指数和CAT评分均下降,且治疗组低于对照组(P<0.05)。治疗组治疗前后肝、肾功能未见明显异常。结论咳喘宁胶囊能有效降低稳定期COPD患者BODE指数及CAT评分,提高患者生活质量和临床疗效,无明显不良反应。
目的:觀察咳喘寧膠囊治療穩定期慢性阻塞性肺疾病(COPD)的臨床療效。方法將110例穩定期COPD患者隨機分為治療組和對照組各55例。2組均予複方異丙託溴銨溶液氣霧吸入,在此基礎上,治療組口服咳喘寧膠囊,每次4粒,每日3次;對照組口服等劑量安慰劑膠囊。療程均為3箇月。觀察2組患者臨床療效、BODE 指數、COPD 評估測試(CAT)評分及不良反應。結果治療組與對照組分彆脫落5、4例。治療組臨床總有效率為96.00%(48/50),對照組為88.24%(45/51),2組比較差異有統計學意義(P<0.05)。2組治療後BODE指數和CAT評分均下降,且治療組低于對照組(P<0.05)。治療組治療前後肝、腎功能未見明顯異常。結論咳喘寧膠囊能有效降低穩定期COPD患者BODE指數及CAT評分,提高患者生活質量和臨床療效,無明顯不良反應。
목적:관찰해천저효낭치료은정기만성조새성폐질병(COPD)적림상료효。방법장110례은정기COPD환자수궤분위치료조화대조조각55례。2조균여복방이병탁추안용액기무흡입,재차기출상,치료조구복해천저효낭,매차4립,매일3차;대조조구복등제량안위제효낭。료정균위3개월。관찰2조환자림상료효、BODE 지수、COPD 평고측시(CAT)평분급불량반응。결과치료조여대조조분별탈락5、4례。치료조림상총유효솔위96.00%(48/50),대조조위88.24%(45/51),2조비교차이유통계학의의(P<0.05)。2조치료후BODE지수화CAT평분균하강,차치료조저우대조조(P<0.05)。치료조치료전후간、신공능미견명현이상。결론해천저효낭능유효강저은정기COPD환자BODE지수급CAT평분,제고환자생활질량화림상료효,무명현불량반응。
Objective To observe the clinical efficacy of Kechuanning capsules for the treatment of chronic obstructive pulmonary disease (COPD) in stable phase.Methods Totally 110 patients with stable COPD were randomly divided into the therapy group and the control group, 55 cases in each group. Patients in both groups were given ipratropium bromide solution for inhalation. On the basis of western medicine treatment, the therapy group took Kechuanning capsules orally at the same time, 4 softgels for each time, 3 times a day;on the basis of western medicine treatment, the control group took the same amount of placebo capsules. The treatment lasted three months. Meanwhile, the clinical efficacy, BODE index, CAT score and ADRs of patients in the two groups were observed.Results The clinical efficacy in the therapy group was 96.00% (48/50), and 88.24% (45/51) in the control group, with statistical significance (P<0.05). BODE index and CAT score in the two groups decreased and the therapy group was lower than the control group (P<0.05). Liver and kidney function had no obvious abnormalities in the treatment group before and after treatment.Conclusion Kechuanning capsules can effectively reduce the BODE index and CAT score in patients with stable COPD, improve patients' life quality and clinical outcomes, and no obvious side effect has been found.